US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Athira Pharma, Inc. - Common Stock
(NQ:
ATHA
)
6.750
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Athira Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”
January 09, 2026
New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
December 18, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Reverse Stock Split
September 11, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
August 14, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
August 07, 2025
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
May 13, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
May 09, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
February 27, 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
December 06, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
November 07, 2024
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
October 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
September 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
July 09, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
May 29, 2024
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
May 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
May 02, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
April 15, 2024
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
April 11, 2024
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
April 03, 2024
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and...
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
February 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
February 08, 2024
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 08, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
